IRIS
ALFIERI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.858
AS - Asia 9.672
EU - Europa 7.531
SA - Sud America 1.277
AF - Africa 494
Continente sconosciuto - Info sul continente non disponibili 353
OC - Oceania 13
Totale 31.198
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.580
SG - Singapore 3.315
CN - Cina 2.729
IT - Italia 1.725
VN - Vietnam 1.581
IE - Irlanda 1.110
FI - Finlandia 1.074
BR - Brasile 1.014
SE - Svezia 941
DE - Germania 752
HK - Hong Kong 674
UA - Ucraina 488
FR - Francia 363
ZA - Sudafrica 311
NL - Olanda 299
BD - Bangladesh 296
TR - Turchia 291
IN - India 211
GB - Regno Unito 193
RU - Federazione Russa 168
CA - Canada 165
AR - Argentina 106
AT - Austria 97
BE - Belgio 85
CI - Costa d'Avorio 74
JP - Giappone 68
IQ - Iraq 63
MX - Messico 60
PL - Polonia 55
ID - Indonesia 54
KR - Corea 54
PK - Pakistan 43
PH - Filippine 41
EC - Ecuador 40
ES - Italia 40
CO - Colombia 36
CZ - Repubblica Ceca 33
TH - Thailandia 30
UZ - Uzbekistan 28
MA - Marocco 27
LT - Lituania 25
VE - Venezuela 23
SA - Arabia Saudita 21
IR - Iran 18
JO - Giordania 17
EG - Egitto 16
KE - Kenya 16
TN - Tunisia 15
PY - Paraguay 14
TW - Taiwan 14
CL - Cile 13
JM - Giamaica 13
MY - Malesia 13
AL - Albania 12
RO - Romania 12
UY - Uruguay 12
AZ - Azerbaigian 11
AE - Emirati Arabi Uniti 10
AU - Australia 9
BO - Bolivia 9
DZ - Algeria 9
HU - Ungheria 9
KZ - Kazakistan 9
LB - Libano 9
NP - Nepal 9
PE - Perù 9
PS - Palestinian Territory 9
GE - Georgia 7
GT - Guatemala 7
HN - Honduras 7
LU - Lussemburgo 7
OM - Oman 7
SY - Repubblica araba siriana 7
EE - Estonia 6
IL - Israele 6
KG - Kirghizistan 6
MD - Moldavia 6
CH - Svizzera 5
CR - Costa Rica 5
ET - Etiopia 5
PA - Panama 5
DO - Repubblica Dominicana 4
NZ - Nuova Zelanda 4
QA - Qatar 4
AM - Armenia 3
AO - Angola 3
BB - Barbados 3
BG - Bulgaria 3
BW - Botswana 3
DK - Danimarca 3
HR - Croazia 3
LV - Lettonia 3
SI - Slovenia 3
SN - Senegal 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
BH - Bahrain 2
CY - Cipro 2
EU - Europa 2
GA - Gabon 2
Totale 30.812
Salva come PNG Salva come JPEG
Città #
Singapore 1.692
Ashburn 1.234
Dublin 1.107
San Jose 1.070
Chandler 1.038
Dallas 954
Santa Clara 669
Beijing 645
Hong Kong 626
Jacksonville 562
Parma 517
Ann Arbor 508
Ho Chi Minh City 482
Council Bluffs 411
Dearborn 397
Boardman 356
Hanoi 340
Johannesburg 299
New York 270
Los Angeles 255
Nanjing 255
Izmir 234
Shanghai 232
Munich 198
Lauterbourg 196
Princeton 196
San Mateo 169
Hefei 141
Bremen 135
Milan 130
Chicago 124
Wilmington 115
Helsinki 108
São Paulo 98
Nanchang 92
Buffalo 88
Kunming 88
Moscow 83
Toronto 83
Shenyang 82
Haiphong 80
Vienna 80
Jinan 76
Abidjan 74
Hebei 74
Woodbridge 69
Brussels 67
Des Moines 67
Bologna 60
Da Nang 60
Marseille 57
Frankfurt am Main 56
Tianjin 56
Rome 54
Houston 50
Seattle 50
The Dalles 49
Columbus 47
Modena 47
Pune 47
Turku 46
Guangzhou 44
Tokyo 44
Jiaxing 42
Warsaw 42
Amsterdam 41
Brooklyn 41
Changsha 41
London 38
Stockholm 35
Jakarta 34
Rio de Janeiro 34
Denver 33
Düsseldorf 30
Phoenix 30
Reggio Emilia 29
Seoul 29
Hangzhou 28
Biên Hòa 27
Montreal 27
Orem 27
Tashkent 27
Norwalk 26
Dhaka 25
Manchester 25
San Francisco 25
Atlanta 24
Belo Horizonte 23
Brasília 23
Hải Dương 23
Levanto 23
Redmond 23
Chennai 22
Leawood 22
Nuremberg 22
Campinas 21
Curitiba 21
Baghdad 20
Fremont 20
Mumbai 20
Totale 18.676
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 353
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 299
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 285
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 254
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 254
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 249
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 222
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 220
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 216
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 215
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 212
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 211
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 211
Allotrapianto di polmone sinistro nel coniglio.Modello sperimentale per lo studio della conservazione del polmone. 211
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 210
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 209
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 208
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 208
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 206
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 206
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 206
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 200
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 200
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 197
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 196
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 196
Characterization of gefitinib uptake in NSCLC cell lines 194
Synthesis of Fe3O4 superparamagnetic nanoparticles and anchoring via ‘click’ chemistry to SiC/SiO2 nanowires for radiofrequency magnetic field hyperthermia 194
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 192
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 192
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 191
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 188
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 187
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 186
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 185
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 185
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 185
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 184
5-benzylidene-hydantoins as new inhibitors of cell proliferation 183
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 180
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 180
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 180
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 180
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 179
Antitumoral effect of a nanotechnology-based photodynamic therapy. 178
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 176
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 176
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 175
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 175
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 174
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 174
An original application of plasma expanders: heart-lung preservation. 170
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 169
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 168
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 168
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 168
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 167
Attenuated expression of 70kDa heat shock protein in WI-38 human fibroblasts during aging in vitro 167
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 166
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 165
Cytocompatibility and Cellular Internalization Mechanisms of SiC/SiO2 Nanowires 165
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 164
Attenuata induzione del gene SNAT-2 in fibroblasti umani senescenti esposti a stress iperosmolare 161
Methodology for the assessment of lung protection. Human pulmonary artery endothelial cell preservation using haemaccel. 161
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 161
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 161
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 160
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 160
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 159
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 159
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 157
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 153
An effective solution for prolonged preservation of cultured human pulmonary artery endothelial cells 152
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 152
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 152
Anti-proliferative and pro-apoptotic effects of soarfenib in MCF-7/AROM-1 breast cancer cells. 151
Synergistic activity of letrozole and sorafenib on breast cancer cells 150
New MDR1 inhibitors for overcoming multidrug resistance 150
SiO2/SiC core-shell nanowires for nanomedicine applications 150
) Sperimentazione su pneumociti di tipo II per la conservazione del polmone in funzione del trapianto. Soluzioni idroelettrolitiche a confronto. 149
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 149
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 149
A new extracellular type solution for lung preservation: "in vitro" comparison with Beltzer, low potassium Dextran and Euro-Collins solutions by means of human lung fibroblasts. 148
Alterazioni della degradazione proteasoma-dipendente nel corso dell'invecchiamento ed effetti delle restrizioni caloriche 148
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 148
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 148
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 148
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 148
Cytocompatible 3C-SiC/SiO2 core shell nanowires for bimodal cancer therapy 147
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 147
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 146
5'-Untranslated region of heat shock protein 70 mRNA drives translation under hypertonic conditions 146
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 145
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 145
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 145
Roles of compatible osmolytes and heat shock protein 70 in the induction of tolerance to stresses in porcine endothelial cells 144
Anti-proliferative effect of induced Fhit expression in non small cell lung cancer cell line (Calu-1) 144
SiO2/SiC core-shell nanowires for nanomedicine applications 144
Activation of heat-shock transcription factor 1 by hypertonic shock in 3T3 cells 142
New treatment opportunities in phosphatase and tensin homolo(PTen)-deficient tumors: Focus on PTen/focal adhesion kinase pathway 141
Totale 17.984
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.607
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 105.607
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022967 0 22 52 65 34 14 135 119 60 71 67 328
2022/20234.206 399 434 276 278 414 466 44 297 1.364 25 169 40
2023/20241.762 86 139 60 64 157 403 129 131 68 88 155 282
2024/20255.391 177 281 345 406 496 566 305 223 737 463 472 920
2025/202611.663 1.026 1.078 1.418 1.061 1.562 659 1.286 362 1.625 864 457 265
2026/2027796 384 412 0 0 0 0 0 0 0 0 0 0
Totale 31.198